

Publication status: This preprint has not been published elsewhere.

# AUTOLOGOUS PLATELET-RICH-FIBRIN IN ESTHETIC MEDICINE: MINI REVIEW ON THE CURRENT DEVELOPMENT STAGE

Gerson Nakazato, Gabriela Durán, Nelson Durán

<https://doi.org/10.1590/SciELOPreprints.13678>

Submitted on: 2025-10-06

Posted on: 2025-12-09 (version 1)

(YYYY-MM-DD)

# AUTOLOGOUS PLATELET-RICH-FIBRIN IN ESTHETIC MEDICINE: MINI REVIEW ON THE CURRENT DEVELOPMENT STAGE

Gabriela Durán<sup>1, \*</sup>, Nelson Durán<sup>2</sup>, Gerson Nakazato<sup>3, \*</sup>

<sup>1</sup>Dr. G. Durán Harmonization and Dental Clinic, Garopaba, SC, Brazil, <sup>2</sup>Laboratory of Urogenital Carcinogenesis and Immunotherapy, Department of Structural and Functional Biology, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil, <sup>3</sup>Laboratory of Basic and Applied Bacteriology, Department of Microbiology, Biology Sciences Center, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil

\*Corresponding Authors: Gabriela Durán, Dra. G. Durán Harmonization and Dental Clinic, Garopaba, SC, Brazil. E-mail: [gabiiduran@hotmail.com](mailto:gabiiduran@hotmail.com). ORCID: <https://orcid.org/0009-0003-1293-1419>. <sup>2</sup>Laboratory of Basic and Applied Bacteriology, Department of Microbiology, <sup>3</sup>Biology Sciences Center, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil. E-mail: [gnakazato@uel.br](mailto:gnakazato@uel.br) ORCID <https://orcid.org/0000-0001-8624-795X>. Nelson Durán ORCID <https://orcid.org/0000-0001-8372-5143>

## ABSTRACT

The present mini-review on the general and specific aspects of the Platelet-rich-fibrin (PRF) application technique adopted for dermatological treatments reports differences between Platelet-rich plasma (PRP) and PRF, their specific applications in dermatology and preparation methods, mainly with respect to PRF. The protocol for patients undergoing treatment and the ethical aspects that must be addressed by treatment specialists, such as the informed consent, is also highlighted. Clinical trials have proven i-PRF (injectable platelet-rich fibrin) to be more effective than PRP in skin regeneration. The i-PRF method accounts for a more sustaining and long-lasting release of growth factors (GFs). Furthermore, it proved more effective in most studies in comparison with PRP. Therefore, it is now acknowledged for its several medical and dermatological applications. Finally, PRP and PRF use seems promising given their favorable, safe, and well-tolerated results in improving facial aging signs.

**KEYWORDS:** Platelet; dermatological; release.

## INTRODUCTION

The concept of using collagen bio-stimulation focused on skin quality emerged in 2019. PLLA (poly-L-lactic acid) and CaHa (calcium hydroxyapatite and PCL

(polycaprolactone) use was a great evolution, mainly when it comes to their application for facial renovation or rejuvenation purpose. The properties of all these bioproducts, such as PLLA, pointed out their efficiency in continuous dermal reconstruction. CaHA, for instance, provides fast volumization and further bio-stimulation. PCL, in its turn, expresses long-lasting clinical outcomes. Overall, biostimulators have shown benefits and secure outlines, as well as high individual fulfillment rates. However, future investigations must focus multicenter and long-term clinical assessments to reinforce the current evidence available (de Oliveira et al., 2025). However, nonsurgical attempts, and the application of PRP made of autologous plasma, were approved for facial skin rejuvenation and for other uses (Banihashemi et al., 2021; Xao et al., 2021; Nanda et al., 2021). PRP importance lies in its wide range of proteins/growth factors, including VEGF (vascular endothelial growth factor), PDGF (platelet-derived growth factor) and TGF $\beta$  (transforming growth factor beta). These factors account for skin rejuvenation based on angiogenesis enhancement, stem cell stimulation, tissue structure change, cell proliferation/regeneration and hyaluronic acid generation (Nanda et al., 2021). Many studies describe the use of anticoagulants and the fast delivery of growth factors as likely PRP drawbacks (Miron et al., 2017a; Shashank and Bhushan, 2021; Dashore et al., 2021). Assumingly, these concerns triggered the need for improving the preparation of second-generation platelets based on blood extraction without anticoagulant and fast direct centrifugation (Miron et al., 2017b). Platelets and leukocytes in second-generation platelet-rich fibrin (PRF) are captured from the fibrin clot and growth factors are gradually released over a controlled period-of-time (Kobayashi et al., 2016). However, this PRF is not necessarily used to activate growth factors. On the other hand, a low platelet yield count could be assessed as likely PRF drawback. Another concept to be observed is the injectable PRF resulting from slow speed centrifugation (Choukroun and Ghanaati, 2018). Some studies address PRF application for facial skin rejuvenation or for other associated recommendations (Liang et al., 2018; Shashank and Bhushan, 2021; Atsu et al., 2023).

The last few years witnessed PRP approval for use in the regenerative field, mainly in esthetic medicine and in skin aging therapy (Malcangi et al., 2025). Besides of this research area also act efficiently on cancer (Luzo et al., 2020, 2023), dental treatment (Durán et al., 2020), trigeminal neuralgia (Durán et al., 2023a) and cardiovascular disease (Durán et al., 2023b). PRP is obtained from the patient's autologous blood, and it has GFs (platelet growth factors) capable of achieving tissue repair and collagen production (Emer, 2019; Kassir et al., 2020; Li et al., 2024). Nevertheless, the latest research shows that another PRF preparation may present significant regenerative properties due to its three-dimensional fibrin matrix, which allows long-lasting GF release and, consequently, leads to more efficient tissue regeneration. PRP is produced through fast centrifugation aimed at separating platelets without clots. PRF, in its turn, is produced by slow centrifugation without anticoagulants to generate fibrin lattice (Chamata et al., 2021; Evans et al., 2021; Phoebe et al., 2024). Lattice entraps GF and leads to its gradual and controlled release. This process is perfect for permanent regenerative procedures. Hassan et al. (2020) made quite good PRF featuring. They have proven PRF greater skin texture improvement and individual satisfaction in comparison with PRP. On the other hand, besides inducing tissue healing due to its structure, PRF also enables the

formation of new blood vessels and controls inflammation processes, which are important total skin recuperation components. Moreover, different research has suggested further PRF progress due to CGF (concentrated growth factors), which normalizes GF concentration and assumingly represents one of the most favorable alternatives in the regenerative field. Although PRP is a feasible option for skin regeneration, PRF accounts for new updates given its fibrin matrix and controlled GF release. Accordingly, PRF or CGF can be a selected choice for long-term therapies that require stronger and more substantial production (Samadi et al., 2019; Cianci et al., 2020; White et al., 2021; Gorodilova et al., 2024).

### **Main Differences between PRP and PRF.**

PRP needs bovine thrombin or calcium chloride, and this is the most important difference between PRF and it. However, the PRF thrombin amounts acting in autologous fibrinogen is totally physiological and does not demand the insertion of external chemical agents (Mohan et al., 2019). Thus, PRF stands out from PRP for its easy preparation, simple administration and low cost (close to zero). Furthermore, it significantly reduces blood biochemical manipulation, as it does not use added ingredients. Another PRF benefit lies in its flexibility and three-dimensional structure, which lead to both cytokine imprisonment and cell moving or migration. PRP, in its turn, is a fibrin condensate that renders polymers denser and turns them into a rigid network. PRF also has receptive effect on the immune system and helps hemostasis (Agrawal and Agrawal, 2014). The comparison between PRP and PRF, and their action in releasing essential growth factors for physiological actions (aimed at wound healing and tissue repair) often show these factors delivered in PRF-generated clots. These delivery factors can be observed for up to ten days, at the amount (Hartshorne and Gluckman, 2016). Their effects are quite similar, namely: they boost cell generation and proteins such as collagen.

The PRP/PRF confrontation is preset, and their easy generation is one of their main gains. PRP needs blood collection and the addition of a non-autogenous, which is an artificial product used to get to the expected outcome, whereas PRF data collection is immediate (Mohan et al., 2019; Garcia, 2023). No non-autogenous product is added to the blood after its collection when PRF is adopted. The tube is placed in the centrifuge (400 x g) for 10 minutes to prepare the product, which must be used within 4 hours after collection. When it comes to PRFM (matrix) preparation, centrifugation must be set at 1100 x g for 6 minutes; the second step is run at 4500 x g for 25 min (See Fig. 1) (Nagaraja et al., 2019).




Fig.1. Schematic diagram representing preparation of platelet-rich fibrin (PRF) and platelet-rich fibrin matrix (PRFM) with resultant matrix. From Nagaraja et al (2019) by permission of Wolters Kluwer - Medknowunder in the terms of the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 License.

The current systematic review focused on assessing all evidence available in all medical fields about PRP efficiency in comparison with the injectable platelet-rich fibrin (i-PRF). According to the conducted search, i-PRF accounted for high platelet concentrations and for a more sustained supply, besides long-term GF release in comparison with PRP, over time. Research carried out *in vitro* showed that i-PRF remarkably improved the activity of many cell types such as skin, cartilage, bone, periodontal cells, and soft tissue cells around dental implants, as well as pulp cells. Clinical assays also recorded superior i-PRF results in skin regeneration. The i-PRF bioproduct allows a more supportive and long-lasting GF delivery. It was more advantageous in most PRP studies. It is currently acknowledged for its several medical and dental applications (Assad et al., 2023; Farshidfar et al., 2025).

## PRF for Skin Rejuvenation

The Choukroun group created a second-generation platelet concentrate known as PRF due to PRP limitations (Choukroun et al., 2006; Dohan et al., 2006ab; Choukroun and Ghanaati, 2018). The group aimed at addressing some of the causes related to traditional PRP treatment. PRF means significant progress in preparation means, since it is prepared through a single centrifugation procedure. It ruled out the need for anticoagulants and for certifying total autologous therapy. In addition, the use of PRF in skin rejuvenation has proven an efficient therapy for several dermatological unrests, including facial acne scars (Gawdat et al., 2014), melasma (Tuknayat et al., 2021), and wound healing post-laser ablative treatments (Maisel-Campbell et al., 2020; Na et al., 2011). Studies have highlighted its role in promoting more efficient and faster healing processes, which turned it into a promising therapeutic option in dermatology. Currently, autologous platelet concentrates have extensive application in facial rejuvenation (Nacopoulos and Vesala 2020; Vesala and

Nacopoulos, 2025). They are adopted either in combination with microneedling for targeted drug delivery or integrated into mesotherapy techniques (Lu and Fuchs, 2014; Sclafani and Azzi, 2015; Maisel-Campbell et al., 2020).

Vesala et al. (2023) assessed twelve individuals with facial wrinkles in the age group 26-71 years. The selected patients underwent three i-PRF treatment sessions at 4-week recess. Photographic documentation and clinical assessment were recorded at each session to capture patients' progression under the applied regimen. Statistical analysis was carried out to provide a better understanding of the therapeutic outcomes. A statistically notable improvement was recorded for skin elasticity and soft wrinkles reduction. None of the patients reported adverse reactions. The literature systematically informs that i-PRF remains as promising PRP alternative across various medical settings because it shows encouraging results, mainly in the dermatology field (Vesala et al., 2023; Vesala and Nacopoulos, 2025).

Comparative analysis was adopted to check the efficiency of autologous i-PRF based on microneedling *versus* microneedling isolation to point out atrophic acne scars (Krishnegowda et al., 2023). A split-face study was carried out with 40 patients presenting atrophic acne scars. The right-side scar (under studied) of each patient was treated with autologous i-PRF injections, and the left side (control) scars were treated with normal saline solution - four months was the treatment time, in both cases. Data assessment was carried out through the Goodman and Baron (GB) scale, based on physician subjective scores and on patient gratification or satisfaction rating. The mean baseline GB grade of each face side was recorded at 3.45 for two months. Results showed significant mean GB grade reduction in the study side (1.47) in comparison with the control side (3.33). The mean patient gratification score was quite higher for the right side (5.95) than for the left side (5.35). According to Krishnegowda et al. (2023), the association between autologous asymmetry improvement correction and natural properties of biologic fillers such as hyaluronic acid, collagen, autologous fat, PRP and PRF, has shown logical and potentially efficient possibilities for facial restoration. Autologous platelet derivatives -enriched with biologically active molecules such as PDGF, transform growth i-PRF and microneedling by synergistically improving acne scars (Vesala and Nacopoulos, 2025).

Recently, an excellent review on PRP and PRF risks and benefits for advanced facial rejuvenation techniques was published (Fagundes and Pepes, 2025). It emphatically highlights the benefits of autologous products. This study's results are provided in the next paragraph.

Santos et al. (2024) emphasized that PRP and PRF are promising techniques with potential benefits to treat facial aging, mainly when it does not relate to wrinkles, hyperpigmentation and skin texture quality. Similarly, Buzalaf and Levy (2022) highlighted that PRP and PRF are safe and well-tolerated products that have impact on facial rejuvenation by boosting collagen production, which gives the skin a more youthful appearance. However, according to them, although these products may present risks, they are considered minimal, mainly in comparison with the benefits of their use. Storrer et al. (2019) mentioned the possibility of risks such as erythema, burning and edema due to these products, but these outcomes are considered transient, for only lasting 1 to 3 days. They emphasize the beneficial effects of PRP and PRF for rejuvenation, mainly for skin texture and elasticity. Phoebe et al. (2024) emphasized PRP effectiveness

to treat facial aging. Collagen synthesis stimulation, which significantly improves skin texture and elasticity, as well as reducing wrinkles and fine lines, is among the advantages of its use. Furthermore, this product is also associated with risks such as pain, discomfort, and bruising, as well as with possible complications like infections and contamination, due to its intradermal administration. Nevertheless, according to the study, PRP is considered safe and has only recorded few reported adverse effects. Sanz and Pinto (2023) conducted a study with PRP in combination with photothermal activation to treat facial sagging. Their results have shown skin laxity decrease, which gave the skin an overall rejuvenated, smoother and more luminous appearance. Like the previous study, this last one also reported a common risk associated with PRP application, namely: mild pain resulting from the injection. However, it reinforces that the use of this autologous product is secure and effective. The clinical trial and literature review conducted by Banihashemi et al. (2021) has proven that PRP injections for facial rejuvenation are a promising technique that presents satisfactory outcomes, mainly for dark circles and periorbital wrinkles. Furthermore, it also showed improvement in nasolabial folds, and in skin quality, texture, and tone. Like the study by Santos et al. (2024), this clinical trial highlighted that no serious or persistent risks were observed. Hersant et al. (2021) administered PRP and HA injections and observed that their synergistic effect enhances the benefits of the autologous component. Improvements in the skin overall appearance, including in texture, radiance, hydration, firmness, and elasticity, are among the benefits from collagen and elastin stimulation. However, there is a risk of adverse reactions, such as mild bruising formation, because this technique depends on injections. This risk is assumingly associated with patients' dermal fragility. Dermal strengthening was observed after the first application and the subsequent cell regeneration stimulation. Chamata et al. (2021) discussed PRP benefits based on the application of different techniques such as microneedling, lasers and intra- and subdermal injections. Overall, all these procedures accounted for remarkable improvements in skin overall appearance, mainly in its texture, color wrinkles, tone, and pores. Although no serious complications were reported, this treatment can cause some adverse effects like transient edema, bruising, erythema, and discomfort. However, these authors emphasized that this technique is safe and effective for facial rejuvenation. Hu et al. (2021) carried out a comparative study on PRF injections and observed that this bioproduct's main role lies in stimulating the collagen and elastin synthesis and, consequently, in working as filler. Benefits resulting from this process include skin quality and texture improvement, and increased skin volume, smoothness, uniformity, and radiance. Therefore, PRF is considered a non-surgical facelift. According to Hassan et al. (2020), injectable PRF really favors facial rejuvenation, and its main effects comprise improved overall skin, spots, pores, texture and wrinkles appearance. Furthermore, their study did not report significant adverse effects; therefore, it was considered a safe procedure. Seoudy et al. (2022) associated PRP with CO<sub>2</sub> laser to maximize the facial aging treatment. They highlighted that the PRP and laser synergistic effect leads to significant collagen synthesis stimulation, and it results in wrinkles and fine lines' mitigation. This technique uses an ablative laser, which can have negative effects like edema and erythema, although these are low-relevance events. Peng (2019) used PRP based on microneedling and intradermal

injections to generate facial rejuvenation. Both methods led to significant results; they improved wrinkles appearance, and facial texture, elasticity, tone and volume due to collagen and elastin synthesis stimulation. However, although these procedures are minimally invasive, there are potential risks such as bruising formation. Almeida et al. (2023) combined PRP and PRF use with HA and CaHA in a clinical case report to maximize these bioproducts' benefits. This technique stimulates collagen and elastin production to promote facial volumization and filling. It reduces sagging, which is a characteristic sign of facial aging.

Briefly, the use of PRP and PRF is promising for being favorable, safe, and well-tolerated to mitigate facial aging signs. Autologous products promote visible improvements in skin quality and texture such as in wrinkles and hyperpigmentation signs due to their filling and collagen-production effects. The combination of autologous products with photothermal activation, HA and lasers enhanced facial rejuvenation results. The same was recorded for PRF in combination with CaHA and HA. However, their use may pose risks (although rare, mild, and transient) such as allergic reactions, which can be treated without sequelae. Thus, according to the integrative review, the analyzed articles mostly emphasize PRP and PRF benefits in comparison with risks associated with facial rejuvenation procedures (Fagundes GF, Pepes, 2025).

Fisher et al (2024) conducted another interesting review and showed different PRF aspects. They also pointed out that there is only one publication focused on a clinical trial carried out *in vivo* to assess the physiological action of PRF therapies. Sclafani et al. (2012) developed restricted pilot research and presented a localized tissue feedback or response following the PRF administration. They found fibroblast energizing and collagen discharge before the seventh therapy day; moreover, there was significant neovascularization nineteen days after its administration. Many research has shown clinical associations with PRF's postulated action mechanism based on qualitative and quantitative skin assessments conducted to substantiate the primary results (Sclafani, 2010; Nacopoulos and Vesala, 2020; Hu et al, 2021) Hu et al. (2021) ran a random study based on placebo-controlled trial and showed a statistically relevant VISIA score improvement in the therapeutic arm (PRFM) in comparison with the control arm three months after treatment.

## **PRF Preparation and Use in Dermatology**

After a long and exhausting basic investigation, Miron et al. (2017a) found that liquid PRP can be produced by additionally decreasing the g force (centrifugal force) and the spinning continuation time. This method was called "Injectable-PRF or i-PRF or I-RPF". The spinning or centrifugal speed remains at 60 g for 3 minutes. This short centrifugation time allows separating the possible clot formation and provides more time for clot formation, although PRF remains liquid. The volume of produced i-PRF in a 10 mL tube is 1-1.5 mL, on average. However, platelets and white blood cells (WBC) concentrations is higher than that of Leukocyte rich PRF (L-PRF). Longer spinning time can increase the number of leukocytes and platelets in the PRF and this change is called A-PRF (see Fig.2). All of these nomenclatures are justified by the fact that different centrifugation methods and time are described by different symbology. The C-PRF, for example, is a protocol (700 g for 8 minutes) that remains liquid

for 15–20 minutes before it coagulates and forms a clot. During this time, the i-PRF can be injected into the scalp or the skin of the face, or it can be mixed with bone grafting materials and molded into the required shape and clot into the desired shape (Dashore et al., 2021).




Figure 2. Shows schematic representation of different types of second-generation platelet concentrates that can be prepared using different centrifugation protocols and tubes. Light yellow represents cell free plasma; orange represents plasma containing predominantly platelets and red represent RBC layer. From Dashore et al. (2021) with permission of Wolters Kluwer - Medknow under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 License.

Monteiro et al. (2025) recently reported a practical guide for PRF production; a white or green tube is used to produce i-PRF. It is featured by lack of additives or silica, so the fibrin coagulation/polymerization time depends on the patient's own response. The tube is made of plastic because glass contains silica in its composition. Collection must be made within three minutes to prevent the coagulation process from starting, since it would stop the components from separating during the centrifugation process. After the collection is over, the tourniquet must be removed from the patient's arm before removing the needle. The number of blood tubes (9 ml or 10 ml) can range from 4 to 8 depending on the clinical need. Choukroun® tubes sold for the PRF Process were green. The S-PRF tube can hold 10 ml of blood. The same manufacturer provides a purple tube called i-PRF+ (13 ml) which is recommended for orthopedic use and for aesthetic procedures. The upper part of centrifugated should be aspirated with the aid of a sterile dropper or syringe with sterile needle, right after the centrifugation procedure. The tube holding centrifuged blood can be kept in a

container filled with ice (storage without agglutination for approximately 10 minutes) to delay i-PRF polymerization (Monteiro et al., 2025).

## Protocol for patients

### What to Expect Before Your PRF Therapy Session (Younger Aesthetic, 2025).

It is necessary to meet a medical provider at any Aesthetics Center or Clinic to discuss all the concerns and goals. The aim of this consultation is to make sure that the PRF therapy will fit the patient well. Patients carrying certain health conditions or blood disorders may need alternative options; therefore, patients' complete medical history is important.

In the days before the appointment:

- Keep well hydrated;
- Prevent alcohol intake and smoking;
- Avoid taking blood-thinning medications.

Being well rested and hydrated ensures a smooth procedure and high-quality blood for PRF administration.

### What Happens During the PRF Therapy

The technique itself is quite fast and negligible invasive. There are some aspects to be considered:

1. **Blood harvest:** A little amount of blood is lost due to routine lab procedure
2. **Centrifugation:** The blood is rapidly centrifuged to separate the PRF from the other elements.
3. **Preparation:** Product generation depends on the procedure plan - PRF is administrated right the way.
4. **Application:** The medical staff or provider administrates the PRF into specific areas.

All these procedures often take approximately 45 – 60 minutes. Most individuals only feel mild discomfort. A topical anesthetic cream can be applied if the patient is sensitive to pain.

### What to Expect After the PRF or PRF Therapy

Patients can return to almost all normal activities on the day after the PRF therapy session; although, the targeted areas may have little swelling, rosiness or painfulness. Overall, these secondary effects vanish within a few days.

There are some post care suggestions to take into consideration, namely:

- Refrain from touching or manipulating the targeted areas;
- Runaway from makeup and or other skincare over the first days after the session;
- Refrain from sun exposure, enforced workouts or extreme temperature environments for 3-4 days;
- Follow all specific care demands described by the medical staff or provider.

Assumingly, the benefits of PRF administration feature the minimal downtime possible. It is essential to feel the subtle improvements within a few days; full-

information outcomes slowly come up over the weeks as collagen is replenished.

Interestingly, many patients find immediate volume improvement after PRF and the skin keeps on improving after some growth factors delivery time.

### **Legal and ethical aspects of PRP or PRF**

Informed consent must be read and signed by the patients, as described by Codorean et al. (2017). An example of it is available at [https://ehr.wrshealth.com/shared/practice-documents/2427375/5322\\_PRP\\_Consent\\_Form\\_HealthCare\\_Stat\\_\(1\).pdf](https://ehr.wrshealth.com/shared/practice-documents/2427375/5322_PRP_Consent_Form_HealthCare_Stat_(1).pdf), and another example in <https://www.prphealth.com/wp-content/uploads/2018/05/PRP-HealthGeneralConsent-Form-V1.pdf>.

### **Conclusion**

PRP is a feasible alternative for skin recuperation, but PRF shows new updates due to its fibrin matrix and controlled GF release. According to these findings, PRF, including CGF, may become an alternative for long-term therapies that require stronger and more substantial production. A systematic review of evidence available in all medical fields about PRP and i-PRF shows that i-PRF produced higher platelet concentrations and provided more sustained and long-term GF releases in comparison with PRP. Studies conducted in *vitro* have shown that i-PRF significantly improves the function of many cell types including skin and cartilage cells. Clinical trials have shown that i-PRF leads to superior skin regeneration outcomes than PRP, and it is currently acknowledged for its application in several medical and dermatological uses. In addition to the properties and to its use in skin rejuvenation, PRF has been proven efficient in treating several dermatological conditions including facial acne scars, melasma and scarring, among others. Besides its fast-healing properties, which have turned it into a promising therapeutic option in dermatology, studies have also related autologous platelets to wide application methods for facial rejuvenation. Different publications described the i-PRF preparation, and standard preparation was specified: low and fast centrifugation (60 x g for 3 min). It remains liquid for 15–20 min before coagulating to form a clot. During this time, the i-PRF can be injected into the scalp or the skin of the face. Finally, many aspects related to security and specialists' ethical behavior are extremely important. The therapy must be preceded by an informed consent form signed by the patient.

**Author contributions:** GD, ND: Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing - original draft, Data, collection and analyses, Formal analysis, supervision of manuscript. Final editing manuscript.

**Declaration of Competing Interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## ACKNOWLEDGEMENT

The present research was carried out with the financial support of the São Paulo Research Foundation - FAPESP, Brazil and National Council for Scientific and Technological Development - CNPq, Brazil.

## DATA AVAILABILITY STATEMENT

The data are available in this manuscript.

## REFERENCES

- Agrawal M, Agrawal V. Platelet-rich fibrin and its applications in dentistry. A review article. *Natl J Med Dent Res* 2014; 2: 51-58. MRN: Njmdr\_231\_14.
- Almeida EPM, Levy FM, Buzalaf MAR. "RichBlend" protocol for full-face filling and collagen biostimulation. *RGO -Rev Gaúcha Odontol (Porto Alegre)* 2023; 71: e20230014. DOI:10.1590/1981-86372023001420210069.
- Assad AL, Suguihara RT, Muknicka DP. iPRF: Uma opção de tratamento estético na harmonização orofacial. *Res Soc Develop* 2023; 12: e136121244082. doi: <http://dx.doi.org/10.33448/rsd-v12i12.44082>.
- Atsu N, Ekinci-Aslanoglu C, Kantarci- Demirkiran B, Caf N, Nuhoglu F. The comparison of platelet-rich plasma versus injectable platelet rich fibrin in facial skin rejuvenation. *Dermatol Ther* 2023; 2023: Article ID 3096698. <https://doi.org/10.1155/2023/3096698>.
- Banihashemi M, Zabolinejad N. Salehi M, Alamdari DH, Nakhaizadeh S. Platelet-rich plasma use for facial rejuvenation: A clinical trial and review of current literature. *Acta BioMedica* 2021; 92: e2021187. doi: 10.23750/abm.v92i2.9687.
- Buzalaf MAR, Levy FM. Autologous platelet concentrates for facial rejuvenation. *J Appl Oral Sci* 2022; 30: e20220020. <https://doi.org/10.1590/1678-7757-2022-0020> .
- Chamata ES, Bartlett EL, Weir D, Rohrich RJ. Platelet-rich plasma: Evolving role in plastic surgery. *Plast Reconstr Surg* 2021; 147: 219–230. doi: 10.1097/PRS.0000000000007509.
- Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: The first introduction to the low speed centrifugation concept. *Eur J Trauma Emerg Surg* 2018; 44: 87–95. doi: 10.1007/s00068-017-0767-9.
- Choukroun J, Diss A, Simonpieri A, Girard M-O, Schoeffler C, Dohan SL, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrates.

Part IV: Clinical effects on tissue healing, *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 101: E56-60. 2006; 101: e56-e60, <https://doi.org/10.1016/j.tripleo.2005.07.011>.

Cianci C, Pappalettera G, Renna G, Casavola C, Laurenziello M, Battista G, et al. Mechanical behavior of PET-G tooth aligners under cyclic loading. *Front Mater* 2020; 7: 104. <https://doi.org/10.3389/fmats.2020.00104>.

Codorean I-B, Cernat E, Popescu D, Sinescu RD, Perlea P. Legal and ethical aspects of platelet-rich plasma. *Rom J Leg Med* 2017; 25: 405-408. doi: 10.4323/rjlm.2017.405.

Dashore S, Chouhan K, Nanda S, Sharma A. Platelet rich fibrin, preparation and use in dermatology. *Indian Dermatol Online J* 2021; 12: S55–S65. doi: 10.4103/idoj.idoj\_282\_21.

de Oliveira IP, Pinheiro BLVC, Ramponi IZ, Fraga NC, Mello LF, Puglia BM, et al. Recent advances in collagen biostimulators for facial rejuvenation: a systematic review in aesthetic dermatology. *Ann Dermatol Sci* 2025; 11:1-9. doi: 10.52338/Aods.2025.4831.

Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006a, 101: e37-44. DOI: 10.1016/j.tripleo.2005.07.008.

Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006b, 101: e45-50. DOI: 10.1016/j.tripleo.2005.07.009.

Durán G, Luzo ACM, Fávaro WJ, Durán N. Nanostructured platelet-rich-plasma: State of art in dental treatments. *Braz. J. Dental Sci.* 2020; 23: 1838. doi: 10.14295/bds.2020.v23i2.1838. ISSN - 2178-6011

Durán N, Fávaro WJ, Durán G, Bísvaro GG, Lemes KC, Luzo ACM. Is an alternative of platelet-rich plasma on trigeminal neuralgia? A Mini-Review. SSRN Preprint. Available at SSRN: 2023a; <https://ssrn.com/abstract=4450203> or <http://dx.doi.org/10.2139/ssrn.4450203>.

Durán N, Fávaro WJ, Luzo ACM. The action of platelet-rich plasma (PRP) in cardiovascular disease treatment. *AJR Preprint Section: Preprints Article* Id: 514, Version: 1, 2023b. DOI: <https://doi.org/10.21467/preprints.514>. URL: <https://preprints.ajr.org/index.php/ap/preprint/view/>.

Emer J. Platelet-Rich Plasma (PRP): Current applications in dermatology. *Skin Ther Lett* 2019; 24: 1–6. PMID: 31584784.

Evans AG, Ivanic MG, Botros MA, Pope RW, Halle BR, Glassman GE, et al. Rejuvenating the periorbital area using platelet-rich plasma: A systematic review and meta-analysis. *Arch Dermatol Res* 2021; 313: 711–727. <https://doi.org/10.1007/s00403-020-02173-z>.

Fagundes GF, Pepes, JPF. Risks and benefits of PRP and PRF in advanced facial rejuvenation techniques: an integrative review. *Aesthet Orofac Sci*.2025; 6: 21-30. <https://doi.org/10.51670/aos.v6i2.243>.

Farshidfar N, Amiri MA, Estrin NE, Ahmad P, Sculean A, Zhang Y et al.. Platelet-rich plasma (PRP) versus injectable platelet-rich fibrin (i-PRF): A systematic review across all fields of medicine. *Periodontology* 2000. 2025; 00:1-31. doi:10.1111/ prd.12626.

Garcia ALP. Evaluation of the differences between platelet-rich plasma (PRP) and platelet-rich fibrin (PRF)., Monography: Faculdade Sete Lagoas (FACSETE), Minas Gerais. Brazil (2023). Accessed August 23, 2025, <https://rdta.facsete.edu.br/monografia/items/show/7629>.

Gawdat HI, Hegazy RA, Fawzy MM, Fathy M. Autologous platelet rich plasma: topical versus intradermal after fractional ablative carbon dioxide laser treatment of atrophic acne scars. *Dermatol Surg* 2014; 40: 152-161. doi: 10.1111/dsu.12392.

Gorodilova AV, Kharisova CB, Osinnikova MN, Kitaeva KV, Filin IY, Mayasin YP, et al. The well-forgotten old: Platelet-rich plasma in modern anti-aging therapy. *Cells* 2024; 13: 1755. <https://doi.org/10.3390/cells13211755>.

Hartshorne J, Gluckman H. A comprehensive clinical review of platelet rich fibrin (PRF) and its role in promoting tissue healing and regeneration in dentistry. Part II: Preparation, optimization, handling and application, benefits, and limitations of PRF. *Int Dent. Afr.* 2018; 6:34-50.

Hassan H, Quinlan DJ, Ghanem A. Injectable platelet-rich fibrin for facial rejuvenation: A prospective, single-center study. *J Cosmet Dermatol* 2020; 19: 3213–3221. <https://doi.org/10.1111/jocd.13692>.

He L, Lin Y, Hu X, Zhang Y, Wu H. A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. *Oral Sur Oral Med Oral Pathol Oral Radiol Endod* 2009;108:707-713. doi:10.1016/j.tripleo.2009.06.044.

Hersant B, Sidahmed-Mezi M, Aboud C, Niddam J, Levy S, Mernier T, et al. Synergistic effects of autologous platelet-rich plasma and hyaluronic acid injections on facial skin rejuvenation. *Aesthet Surg J* 2021; 41(7): NP854-865. doi: 10.1093/asj/sjab061

- Hu S, Bassiri-Tehrani M, Abraham MT. The effect of platelet-rich fibrin matrix on skin rejuvenation: A split-face comparison. *Aesthet Surg J* 2021; 41: 747-758, doi: 10.1093/asj/sjaa244.
- Kassir M, Kroumpouzou G, Puja P, Katsambas A, Galadari H, Lotti T, et al. Update in minimally invasive periorbital rejuvenation with a focus on platelet-rich plasma: A narrative review. *J Cosmet Dermatol* 2020; 19: 1057–1062. <https://doi.org/10.1111/jocd.13376>.
- Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, et al., Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Invest* 2016; 20: 2353–2360. doi: 10.1007/s00784-016-1719-1.
- Krishnegowda R, Pradhan SN, Belgaumkar VA. A split-face study to evaluate efficacy of autologous injectable platelet-rich fibrin with microneedling against microneedling with normal saline (placebo control) in atrophic acne scars. *Dermatol Surg* 2023; 49: 938-942. doi: 10.1097/dss.0000000000003893.
- Li Y, Wang X, Li Y, Li D, Li S, Shen C. Efficacy, and safety of allogeneic platelet-rich plasma in chronic wound treatment: A meta-analysis of randomized controlled trials. *Sci Rep* 2024; 14: 25209. <https://doi.org/10.1038/s41598-024-75090-0>.
- Liang ZJ, Lu X, Li DQ, Liang YD, Zhu DD, Wu FX, et al., Precise intradermal injection of nanofat-derived stromal cells combined with platelet-rich fibrin improves the efficacy of facial skin rejuvenation. *Cell Physiol Biochem* 2018; 47: 316-329. doi: 10.1159/000489809.
- Lu C, Fuchs E. Sweat gland progenitors in development, homeostasis, and wound repair. *Cold Spring Harb Perspect Med* 2014; 4: a015222. doi: 10.1101/cshperspect.a015222.
- Luzo, A.C.M., Fávoro, W.J., Seabra, A.B., Durán, N. What is the potentiality of platelet-rich-plasma in cancer treatment? A review. *Heliyon*. 2020; 6: e03660. <https://doi.org/10.1016/j.heliyon.2020.e03660>.
- Luzo ACM, Leme, KC, Fávoro WJF, Durán N, Bísaro, GG, de Oliveira A.LR , Boumediene K, Hammad M, Baugé C. Platelet-rich plasma, their growth factors, cytokines and clinical use. In *Nanotechnology and Regenerative Medicine History, Techniques, Frontiers, and Applications* (Ed. M.H.A. Santana, E. Souto, R. Shegoka) Academic Press, Chapter 11 , pp 265-314, 2023. SBN-13: 978-0323904711, ISBN-10: 0323904718.
- Maisel-Campbell AL, Ismail A, Reynolds KA, Poon E, Serrano L, Grushchak S, et al. A systematic review of the safety and effectiveness of platelet-rich

plasma (PRP) for skin aging. *Arch Dermatol Res* 2020; 312: 301-315. doi: 10.1007/s00403-019-01999-6.

Malcangi G, Inchingolo AM, Inchingolo AD, Ferrante L, Latini G, Trilli I, et al. The Role of platelet concentrates and growth factors in facial rejuvenation: A systematic review with case series. *Medicina* 2025, 61, 84. [https://doi.org/ 10.3390/medicina61010084](https://doi.org/10.3390/medicina61010084).

Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al., "Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry?" *Clin Oral Invest* 20-17a; 21: 2619–2627. doi: 10.1007/s00784-017-2063-9.

Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J. Platelet-rich fibrin and soft tissue wound healing: A systematic review. *Tissue Eng Part B Rev* 2017b; 23:83–99. doi: 10.1089/ten.TEB.2016.0233.

Mohan SP, Jaishangar N, Devy S, Narayanan A., Cherian D, Madhavan S. Platelet-rich plasma and platelet-rich fibrin in periodontal regeneration: A review. *J Pharm Bioallied Sci* 2019; 11: 5126-5130, 2019. doi: 10.4103/JPBS.JPBS\_41\_19.

Monteiro RJSV, Laia BS, Freitas BA, Silva FS, Barroso VH, Braga KM, et al. Practice guideline for obtaining platelet-rich fibrin (PRF). *Braz. J. Surg. Clin. Res.* 2025; 50: 12-17. ISSN on-line: 2317-4404.

Na JI, Choi JW, Choi HR, Jeong JB, Park KC, Youn SW, et al. Rapid healing and reduced erythema after ablative fractional carbon dioxide laser resurfacing combined with the application of autologous platelet-rich plasma. *Dermatol Surg* 2011; 37: 463-468. doi: 10.1111/j.1524-4725.2011.01916.x.

Nacopoulos C, Vesala A. M. Lower facial regeneration with a combination of platelet-rich fibrin liquid matrices based on the low speed centrifugation concept-Cleopatra technique. *J Cosmet Dermatol* 2020; 19: 185-189. doi: 10.1111/jocd.13196.

Nagaraja S, Mathew S, Rajaram RB, Pushpalatha C, Abraham A, Chandanala S. Evaluation of histological and pH changes in platelet-rich fibrin and platelet-rich fibrin matrix: A in vitro study. *Contemp Clin Dent* 2019; 10:652-657. doi: 10.4103/ccd.ccd\_10\_19.

Nanda S, Chauhan K, Shetty V, Dashore S, Bhatia S. Platelet-rich plasma in aesthetics. *Indian Dermatol Online J* 2021; 12: S41–S54. doi: 10.4103/idoj.idoj\_290\_21.

Peng GL. Platelet-rich plasma for skin rejuvenation: Facts, fiction, and pearls for practice. *Facial Plast Surg Clin North Amer* 2019; 27: 405–411. doi: 10.1016/j.fsc.2019.04.006.

- Phoebe LKW, Lee KWA, Chan LKW, Hung LC, Wu R, Wong S, et al. Use of platelet rich plasma for skin rejuvenation. *Skin Res Technol* 2024; 30: e13714. doi: 10.1111/srt.13714.
- Samadi P, Sheykhasan M, Khoshinani HM. The use of platelet-rich plasma in aesthetic and regenerative medicine: A comprehensive review. *Aesthet Plast Surg* 2019; 43: 803–814. <https://doi.org/10.1007/s00266-018-1293-9>.
- Santos LC, Lana GL, Santos GS, Visoni SBC, Brigagão RJ, Santos N, et al. The biological role of platelet derivatives in regenerative aesthetics. *Inter J Mol Sci* 2024; 25: 5604. doi: 10.3390/ijms25115604.
- Sanz CH, Pinto H. Efficacy of photo-thermal-bioactivated platelet-rich plasma for skin biostimulation in patients not eligible for other medical-aesthetic treatment: A pilot study. *Skin Res Technol* 2023; 29: e13412. doi: 10.1111/srt.13412.
- Sclafani AP, Azzi J. Platelet preparations for use in facial rejuvenation and wound healing: A critical review of current literature. *Aesthet Plast Surg* 2015; 39: 495-505. doi: 10.1007/s00266 015-0504-x.
- Sclafani AP. Platelet-rich fibrin matrix for improvement of deep nasolabial folds. *J Cosmet Dermatol* 2010;9(1):66–71. <https://doi.org/10.1111/j.1473-2165.2010.00486.x>.
- Sclafani AP, McCormick SA. Induction of dermal collagenesis, angiogenesis, and adipogenesis in human skin by injection of platelet-rich fibrin matrix. *Arch Facial Plast Surg* 2012;14(2):132–136. <https://doi.org/10.1001/archfacial.2011.784>.
- Seoudy WM, El Messallamy HS, Youssef SS, Zaki MSE. Fractional carbon dioxide laser versus combined fractional CO2 laser and platelet rich plasma in treatment of facial wrinkles: A comparative split face study. *J Cosmet Dermatol* 2023; 22: 837–849. doi: 10.1111/jocd.15500.
- Shashank B, Bhushan M. Injectable Platelet-rich fibrin (PRF): The newest biomaterial and its use in various dermatological conditions in our practice: A case series. *J Cosmetic Dermatol* 2021; 20: 1421–1426. <https://doi.org/10.1111/jocd.13742>.
- Storrer CLM, Andrade CF, Chaves LHK, Wambier LM, De-Geus JL, Zielak JC. Injection of platelet aggregates in facial rejuvenation: a systematic review. *Rev. Bras. Cir. Plást.* 2019; 34: 274-282. <https://doi.org/10.5935/2177-1235.2019RBCP0145>.
- Tuknayat A, Bhalla M, Thami GP. Platelet-rich plasma is a promising therapy for melasma. *J Cosmet Dermatol* 2021; 20: 2431-2436. doi: 10.1111/jocd.14229.

Vesala AM, Nacopoulos C. 2025. Microneedling and injectable-Platelet Rich Fibrin for Skin Rejuvenation and Regeneration. *Med Res Arch* 2025; 13: 1-7. <https://doi.org/10.18103/mra.v13i5.6578>.

Vesala A-M, Nacopoulos C, Karypidis D, Ruga E. Efficacy of microneedling with injectable platelet rich fibrin (i-PRF) for facial skin rejuvenation. *Inter J Dermatol Venereol* 2023; 6: O. doi: 10.1097/jd9.0000000000000301.

White C, Brahs A, Dorton D, Witfill K. Platelet-rich plasma: A comprehensive review of emerging applications in medical and aesthetic dermatology. *J Clin Aesthet Dermatol* 2021; 14: 44–57. PMID: 34980960.

Xiao H, Xu D, Mao R, Xiao M, Fang Y, Liu Y. Platelet-rich plasma in facial rejuvenation: a systematic appraisal of the available clinical evidence. *Clin Cosmetic Investig Dermatol* 2021; 14: 1697–1724, 2021. doi: 10.2147/CCID.S340434.

Younger Aesthetic. What to expect before, during, and after a PRF Therapy. <https://younger-aesthetics.com/prf-therapy-full-process-guide/>. Accessed August 25, 2025.

This preprint was submitted under the following conditions:

- The authors declare that the necessary Terms of Free and Informed Consent of participants or patients in the research were obtained and are described in the manuscript, when applicable.
- The authors declare that the preparation of the manuscript followed the ethical norms of scientific communication.
- The authors declare that they are aware that they are solely responsible for the content of the preprint and that the deposit in SciELO Preprints does not mean any commitment on the part of SciELO, except its preservation and dissemination.
- The authors declare that the data, applications, and other content underlying the manuscript are referenced.
- The deposited manuscript is in PDF format.
- The authors declare that the research that originated the manuscript followed good ethical practices and that the necessary approvals from research ethics committees, when applicable, are described in the manuscript.
- The authors declare that once a manuscript is posted on the SciELO Preprints server, it can only be taken down on request to the SciELO Preprints server Editorial Secretariat, who will post a retraction notice in its place.
- The authors agree that the approved manuscript will be made available under a [Creative Commons CC-BY](#) license.
- The submitting author declares that the contributions of all authors and conflict of interest statement are included explicitly and in specific sections of the manuscript.
- The authors declare that the manuscript was not deposited and/or previously made available on another preprint server or published by a journal.
- If the manuscript is being reviewed or being prepared for publishing but not yet published by a journal, the authors declare that they have received authorization from the journal to make this deposit.
- The submitting author declares that all authors of the manuscript agree with the submission to SciELO Preprints.